http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Li Li,Xiaodong Yin,Hai Meng,Juanyu Hu,Zhengqing Yu,Jianyong Xu 연세대학교의과대학 2020 Yonsei medical journal Vol.61 No.1
Purpose: The purpose of this study was to assess the diagnostic and prognostic value of serum progastrin-releasing peptide(ProGRP) in patients with gastric cancer (GC). Materials and Methods: A total of 150 patients with GC (89 males and 61 females) were recruited, including those with stage I(n=28), stage II (n=33), stage III (n=50), and stage IV (n=39) disease; 50 healthy controls and 66 patients with benign gastric diseaseswere also enrolled. Levels of serum ProGRP, carcinoembryonic antigen (CEA), and carbohydrate antigen 72-4 (CA72-4)were measured in all subjects. Results: Serum ProGRP levels were significantly higher in GC patients than in controls (p<0.001), and ProGRP was significantlycorrelated with tumor size, tumor node metastasis stage, differentiation, invasion depth, and lymph node metastasis (p< 0.005). ProGRP levels were significantly decreased after chemotherapy (p<0.001). Receiver operating characteristic curves revealed a sensitivityand specificity for serum ProGRP in GC of 85.9% and 81.2%, respectively. ProGRP levels were positively correlated withCA72-4 and CEA (r=0.792 and 0.688, p<0.05, respectively). Combined detection of ProGRP, CEA, and CA72-4 showed the best diagnosticpower for GC. Conclusion: ProGRP may be useful as a potential biomarker for GC diagnosis and therapy.